Cleo Diagnostics (ASX:COV) Equity-to-Asset : 0.98 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cleo Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$10.54 Mil. Cleo Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was A$10.74 Mil.

The historical rank and industry rank for Cleo Diagnostics's Equity-to-Asset or its related term are showing as below:

ASX:COV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.88 Med: -0.26 Max: 0.98
Current: 0.98

During the past 1 years, the highest Equity to Asset Ratio of Cleo Diagnostics was 0.98. The lowest was -0.88. And the median was -0.26.

ASX:COV's Equity-to-Asset is ranked better than
99.66% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs ASX:COV: 0.98

Cleo Diagnostics Equity-to-Asset Historical Data

The historical data trend for Cleo Diagnostics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Equity-to-Asset Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Equity-to-Asset

-0.88

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Equity-to-Asset	-0.26	-0.88	0.98

Competitive Comparison of Cleo Diagnostics's Equity-to-Asset

For the Medical Devices subindustry, Cleo Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Equity-to-Asset falls into.

Cleo Diagnostics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cleo Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.943	/	1.077
	=

Cleo Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	10.54	/	10.739
	=

Cleo Diagnostics (ASX:COV) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cleo Diagnostics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines